Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

A study published in Nature Chemistry by researchers from the University of Pittsburgh and Yale University shows how common ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These include oncology and immunology, the primary focuses of the company's internal ...

New center will use cutting-edge AI to accelerate the creation of life-saving medicines AI Small Molecule Drug Discovery ...

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross ...

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target ...

The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials. Isomorphic Labs was ...

The event, held in the emblematic Casa de Convalescència, was supported by the BBVA Foundation and welcomed 150 international ...

A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.